Ratings Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Delayed Nasdaq Other stock markets 20:46:03 02/05/2024 BST			5-day change	1st Jan Change
13.31 ^USD	+5.13%		+11.95%	-26.56%

03-12	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
03-05	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PLIANT THERAPEUTICS, INC.	-26.56%	764M	C-
ELI LILLY AND COMPANY	+29.81%	699B	C+
NOVO NORDISK A/S	+25.07%	571B	B
JOHNSON & JOHNSON	-4.77%	364B	C+
MERCK & CO., INC.	+17.84%	326B	B-
ABBVIE INC.	+3.46%	286B	C+
ASTRAZENECA PLC	+14.68%	236B	B+
NOVARTIS AG	+4.71%	198B	B-
ROCHE HOLDING AG	-12.43%	194B	A+
PFIZER, INC.	-3.77%	154B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes